Educating the general population on the safe and best use of lipid-lowering agents is imperative ... it will be crucial for patients to be well informed about lipid-lowering therapies before ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

A Phase III trial of the antisense agent mipomersen in patients ... once a week by injection) to the lipid-lowering therapy currently used by the patients (such as statins and ezetimibe) resulted ...

As such, pitavastatin shows distinctive pharmacokinetic and clinical profiles that should help a greater proportion of dyslipidemic patients attain ... a need for new agents to manage dyslipidemia.

BASs are the only class of lipid-lowering agents shown to improve LDL-C and glycemic control in patients with Type 2 diabetes mellitus. Colesevelam HCl is the only drug currently approved by the ...

The largest study to date suggests that patients at high risk for heart attacks and strokes should begin immediate treatment with a combination of a statin and ezetimibe. The largest study to date exa ...

Combination lipid-lowering therapy (LLT) is associated with a greater reduction in LDL-C compared with statin monotherapy.

CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein (a), with ...

"Patients with ACS are at the highest risk ... ≥70 mg/dL are strongly urged to take a concurrent non-statin lipid-lowering ...

HealthDay News — Combination lipid-lowering therapy (LLT ... with 108,373 very high-risk patients to examine the efficacy of combination LLT compared to statin monotherapy for LDL-C reduction ...